Abstract
Background: There is limited information regarding the angiographic and clinical outcomes among the different drug-eluting stents (DESs) in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods and Results: A total 355 consecutive AMI patients who underwent PCI with a sirolimus- (SES, n=116) or paclitaxel- (PES, n=153) or zotarolimus-eluting stent (ZES, n=86) were enrolled. The 6-month angiographic and 1-year clinical outcomes were compared among the 3 groups. At 6 months, there was a trend toward a higher incidence of binary restenosis in the PES group (SES: 8.6%, PES: 19.8%, ZES: 8.3%, P=0.052). Percentage of restenosis was higher in the PES group compared with SES, but was similar to ZES (SES: 18.75±18.16%, PES: 29.32±24.16%, ZES: 23.91±17.03%, P=0.006). Late loss was lower in the SES group compared with PES and ZES (SES: 0.44±0.52, PES: 0.83±0.87, ZES: 0.75±0.63, P<0.001). However, clinical outcomes, including mortality, MI, repeat PCI and major adverse cardiac events, were not different among the 3 groups. Conclusions: The angiographic benefit of SES did not translate into a clinical benefit for up to 1 year in AMI patients.
| Original language | English |
|---|---|
| Pages (from-to) | 2229-2235 |
| Number of pages | 7 |
| Journal | Circulation Journal |
| Volume | 73 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 2009 Dec 1 |
Fingerprint
Keywords
- Acute myocardial infarction
- Paclitaxel-eluting stents
- Sirolimus-eluting stents
- Zotarolimus-eluting stents
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Lack of clinical benefit of improved angiographic results with sirolimus-eluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention. / Choi, Cheol Ung; Rha, Seung-Woon; Chen, Kang Yin; Li, Yong Jian; Poddar, Kanhaiya L.; Jin, Zhe; Minami, Yoshiyasu; Suh, Soon Yong; Na, Jin Oh; Lim, Hong Euy; Kim, Jin Won; Kim, Eung Ju; Park, Chang Gyu; Seo, Hong Seog; Oh, Dong Joo.
In: Circulation Journal, Vol. 73, No. 12, 01.12.2009, p. 2229-2235.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lack of clinical benefit of improved angiographic results with sirolimus-eluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention
AU - Choi, Cheol Ung
AU - Rha, Seung-Woon
AU - Chen, Kang Yin
AU - Li, Yong Jian
AU - Poddar, Kanhaiya L.
AU - Jin, Zhe
AU - Minami, Yoshiyasu
AU - Suh, Soon Yong
AU - Na, Jin Oh
AU - Lim, Hong Euy
AU - Kim, Jin Won
AU - Kim, Eung Ju
AU - Park, Chang Gyu
AU - Seo, Hong Seog
AU - Oh, Dong Joo
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Background: There is limited information regarding the angiographic and clinical outcomes among the different drug-eluting stents (DESs) in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods and Results: A total 355 consecutive AMI patients who underwent PCI with a sirolimus- (SES, n=116) or paclitaxel- (PES, n=153) or zotarolimus-eluting stent (ZES, n=86) were enrolled. The 6-month angiographic and 1-year clinical outcomes were compared among the 3 groups. At 6 months, there was a trend toward a higher incidence of binary restenosis in the PES group (SES: 8.6%, PES: 19.8%, ZES: 8.3%, P=0.052). Percentage of restenosis was higher in the PES group compared with SES, but was similar to ZES (SES: 18.75±18.16%, PES: 29.32±24.16%, ZES: 23.91±17.03%, P=0.006). Late loss was lower in the SES group compared with PES and ZES (SES: 0.44±0.52, PES: 0.83±0.87, ZES: 0.75±0.63, P<0.001). However, clinical outcomes, including mortality, MI, repeat PCI and major adverse cardiac events, were not different among the 3 groups. Conclusions: The angiographic benefit of SES did not translate into a clinical benefit for up to 1 year in AMI patients.
AB - Background: There is limited information regarding the angiographic and clinical outcomes among the different drug-eluting stents (DESs) in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods and Results: A total 355 consecutive AMI patients who underwent PCI with a sirolimus- (SES, n=116) or paclitaxel- (PES, n=153) or zotarolimus-eluting stent (ZES, n=86) were enrolled. The 6-month angiographic and 1-year clinical outcomes were compared among the 3 groups. At 6 months, there was a trend toward a higher incidence of binary restenosis in the PES group (SES: 8.6%, PES: 19.8%, ZES: 8.3%, P=0.052). Percentage of restenosis was higher in the PES group compared with SES, but was similar to ZES (SES: 18.75±18.16%, PES: 29.32±24.16%, ZES: 23.91±17.03%, P=0.006). Late loss was lower in the SES group compared with PES and ZES (SES: 0.44±0.52, PES: 0.83±0.87, ZES: 0.75±0.63, P<0.001). However, clinical outcomes, including mortality, MI, repeat PCI and major adverse cardiac events, were not different among the 3 groups. Conclusions: The angiographic benefit of SES did not translate into a clinical benefit for up to 1 year in AMI patients.
KW - Acute myocardial infarction
KW - Paclitaxel-eluting stents
KW - Sirolimus-eluting stents
KW - Zotarolimus-eluting stents
UR - http://www.scopus.com/inward/record.url?scp=73349098402&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73349098402&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-08-1086
DO - 10.1253/circj.CJ-08-1086
M3 - Article
VL - 73
SP - 2229
EP - 2235
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 12
ER -